CN117297996A - Hirudin freeze-dried mask and preparation method thereof - Google Patents
Hirudin freeze-dried mask and preparation method thereof Download PDFInfo
- Publication number
- CN117297996A CN117297996A CN202310003683.5A CN202310003683A CN117297996A CN 117297996 A CN117297996 A CN 117297996A CN 202310003683 A CN202310003683 A CN 202310003683A CN 117297996 A CN117297996 A CN 117297996A
- Authority
- CN
- China
- Prior art keywords
- parts
- mask
- hirudin
- freeze
- dried
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000007625 Hirudins Human genes 0.000 title claims abstract description 82
- 108010007267 Hirudins Proteins 0.000 title claims abstract description 82
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 title claims abstract description 82
- 229940006607 hirudin Drugs 0.000 title claims abstract description 82
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 35
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 230000003712 anti-aging effect Effects 0.000 claims abstract description 9
- 230000002087 whitening effect Effects 0.000 claims abstract description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 54
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 36
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 36
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 36
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 24
- 102000008186 Collagen Human genes 0.000 claims description 24
- 108010035532 Collagen Proteins 0.000 claims description 24
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 24
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 24
- 229920001436 collagen Polymers 0.000 claims description 24
- 239000000047 product Substances 0.000 claims description 24
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 24
- 235000011187 glycerol Nutrition 0.000 claims description 23
- 239000000463 material Substances 0.000 claims description 21
- 238000001035 drying Methods 0.000 claims description 18
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 16
- 230000001815 facial effect Effects 0.000 claims description 16
- 239000004744 fabric Substances 0.000 claims description 15
- 238000000859 sublimation Methods 0.000 claims description 15
- 230000008022 sublimation Effects 0.000 claims description 15
- CLAHOZSYMRNIPY-UHFFFAOYSA-N 2-hydroxyethylurea Chemical compound NC(=O)NCCO CLAHOZSYMRNIPY-UHFFFAOYSA-N 0.000 claims description 12
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 12
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 12
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 12
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 12
- 229930195725 Mannitol Natural products 0.000 claims description 12
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims description 12
- 241000221095 Simmondsia Species 0.000 claims description 12
- 235000004433 Simmondsia californica Nutrition 0.000 claims description 12
- 241001506047 Tremella Species 0.000 claims description 12
- 229960003237 betaine Drugs 0.000 claims description 12
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 12
- 235000013399 edible fruits Nutrition 0.000 claims description 12
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 12
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 12
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 12
- 229940031575 hydroxyethyl urea Drugs 0.000 claims description 12
- 239000000594 mannitol Substances 0.000 claims description 12
- 235000010355 mannitol Nutrition 0.000 claims description 12
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 12
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 12
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 12
- 229940049964 oleate Drugs 0.000 claims description 12
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 12
- 238000004806 packaging method and process Methods 0.000 claims description 12
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 12
- 229940032094 squalane Drugs 0.000 claims description 12
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 10
- 230000001954 sterilising effect Effects 0.000 claims description 10
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 229960000458 allantoin Drugs 0.000 claims description 8
- 239000008367 deionised water Substances 0.000 claims description 8
- 229910021641 deionized water Inorganic materials 0.000 claims description 8
- 239000012153 distilled water Substances 0.000 claims description 6
- 238000007789 sealing Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 4
- 238000011049 filling Methods 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 239000011148 porous material Substances 0.000 claims description 4
- 239000011265 semifinished product Substances 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- XWZAWHJNTHSHGD-SIDOVBMKSA-N (2S)-6-amino-N-[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]propanoyl]amino]hexanamide Polymers CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccccc1)C(N)=O XWZAWHJNTHSHGD-SIDOVBMKSA-N 0.000 claims description 2
- 229910017052 cobalt Inorganic materials 0.000 claims description 2
- 239000010941 cobalt Substances 0.000 claims description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 2
- 239000008213 purified water Substances 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 29
- 239000003755 preservative agent Substances 0.000 abstract description 6
- 238000002474 experimental method Methods 0.000 abstract description 5
- 230000002335 preservative effect Effects 0.000 abstract description 4
- 239000002537 cosmetic Substances 0.000 abstract description 3
- 230000007547 defect Effects 0.000 abstract description 3
- 238000003860 storage Methods 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 27
- 238000000034 method Methods 0.000 description 15
- 238000002835 absorbance Methods 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 12
- 239000002994 raw material Substances 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 239000007788 liquid Substances 0.000 description 8
- 231100000430 skin reaction Toxicity 0.000 description 8
- 206010040914 Skin reaction Diseases 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 230000035483 skin reaction Effects 0.000 description 7
- 108090000190 Thrombin Proteins 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000001953 sensory effect Effects 0.000 description 6
- 229960004072 thrombin Drugs 0.000 description 6
- 206010008570 Chloasma Diseases 0.000 description 5
- 208000003351 Melanosis Diseases 0.000 description 5
- 230000010100 anticoagulation Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000012488 sample solution Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 241000700198 Cavia Species 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 102000003425 Tyrosinase Human genes 0.000 description 4
- 108060008724 Tyrosinase Proteins 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000001877 deodorizing effect Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000008099 melanin synthesis Effects 0.000 description 4
- 231100000444 skin lesion Toxicity 0.000 description 4
- 206010040882 skin lesion Diseases 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000237903 Hirudo Species 0.000 description 3
- 239000004019 antithrombin Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- -1 hydroxyl radicals Chemical class 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 241000545744 Hirudinea Species 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 229960000271 arbutin Drugs 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000004332 deodorization Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- HEILIGJNYTWOHU-UHFFFAOYSA-N ethanol 2-hydroxybenzoic acid Chemical compound CCO.OC(=O)C1=CC=CC=C1O HEILIGJNYTWOHU-UHFFFAOYSA-N 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- OCZVHBZNPVABKX-UHFFFAOYSA-N 1,1-diphenyl-2-(2,4,6-trinitrophenyl)hydrazine;ethanol Chemical compound CCO.[O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NN(C=1C=CC=CC=1)C1=CC=CC=C1 OCZVHBZNPVABKX-UHFFFAOYSA-N 0.000 description 1
- DUIOKRXOKLLURE-UHFFFAOYSA-N 2-octylphenol Chemical compound CCCCCCCCC1=CC=CC=C1O DUIOKRXOKLLURE-UHFFFAOYSA-N 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241000243818 Annelida Species 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000002506 anticoagulant protein Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940127217 antithrombotic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000036564 melanin content Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012802 pre-warming Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 238000011120 smear test Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/30—Characterized by the absence of a particular group of ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/84—Products or compounds obtained by lyophilisation, freeze-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/87—Application Devices; Containers; Packaging
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a hirudin freeze-dried mask and a preparation method thereof, and experiments prove that the hirudin mask prepared by the preparation method of the hirudin freeze-dried mask has definite anti-aging and whitening effects; overcomes the defects that hirudin is unstable and easy to be deactivated in water, and has fishy smell at normal temperature; the fishy smell is purified and removed, and then the fishy smell is prepared into a freeze-dried mask for storage and use, so that the stability is improved, and the problem that the active ingredients added into cosmetics cannot be stored for a long time and the smell is solved; the freeze-dried mask provided by the invention has stable and effective activity, avoids the addition of unnecessary preservative and the like, and reduces the skin burden.
Description
Technical Field
The invention belongs to the technical field of skin care products and preparation thereof, and particularly relates to a hirudin freeze-dried mask and a preparation method thereof.
Background
The facial mask is a facial skin cosmetic which is coated on the surface of human skin, is removed, scrubbed or reserved after a period of time, and has the functions of centralized cleaning, nursing and nutrition, and is popular with adults, especially female consumers. With the maturity of consumption psychology, people not only require the basic effects of cleaning, nursing and nutrition of the facial mask, but also further pursue the advanced effects of whitening, anti-aging and the like of the development facial mask. At present, the types of facial masks are various and are divided into a sticking facial mask, a tearing facial mask, a gel facial mask, a freeze-drying facial mask and the like. The freeze-dried mask is also called as freeze-dried powder mask and freeze-dried solid stock solution mask, and is formed by fusing components such as stock solution of the mask, a thickening agent, a humectant and the like with film cloth fibers, and sublimating moisture by vacuum freeze drying to form a solid dry film type mask. After the face is cleaned, the freeze-dried mask is directly taken out and applied on the face, the rest of the mask stays for about 20 minutes, and the rest of the mask is gently massaged and can be applied on hands and feet or other parts of the body. After the essence on the face is massaged and absorbed, the face is cleaned by clear water, and meanwhile, due to the good physical property of the freeze-dried mask, the freeze-dried mask can become a good medicine carrier, and different medicines are added into the freeze-dried mask, so that multiple effects of moisturizing and beautifying can be achieved.
Leech belongs to a highly specialized annelid animal, is originally carried in Shennong Ben Cao Jing (Shen nong's herbal), is commonly called Hirudo, and is a traditional Chinese medicine in China, salty in taste, bitter in taste and flat in nature. The pharmacopoeia of the people's republic of China has the curative effects of breaking blood, removing blood stasis and dredging channels, and is mainly used for treating tumor, masses, blood stasis, amenorrhea and traumatic injury. In 1884, haycraft first found a bioactive substance hirudin in the salivary glands of European medical leeches. In 1927, shionoya was first studied as an antithrombotic drug. 1955 Markwards indicates that it is a proteinaceous material and is designated hirudin. The natural hirudin is an anticoagulant protein extracted from medical Hirudo, and is a single-chain polypeptide composed of 65 or 66 amino acid residues, and has a relative molecular mass of 7000Dalton.
Hirudin itself has a strong fishy smell and is difficult to apply to skin care products; in the prior art, hirudin is applied to a mask, and is mainly used for a common patch mask and a smearing mask, which belong to a liquid environment, and a certain amount of preservative is required to be added. Part of human skin has irritation, allergy and other reactions to preservatives. Hirudin is a polypeptide which is also susceptible to inactivation and deterioration in a liquid environment.
Disclosure of Invention
In order to solve the technical problems, the invention provides a freeze-dried mask using hirudin as an active ingredient, which has definite anti-aging and whitening effects through experiments; overcomes the defects that hirudin is unstable and easy to be deactivated in water, and has fishy smell at normal temperature; the fishy smell is purified and removed, and then the fishy smell is prepared into a freeze-dried mask for storage and use, so that the stability is improved, and the problem that the active ingredients added into cosmetics cannot be stored for a long time and the smell is solved; the freeze-dried mask provided by the invention has stable and effective activity, avoids the addition of unnecessary preservative and the like, and reduces the skin burden.
In order to achieve the technical purpose, the invention is realized by the following technical scheme: a hirudin lyophilized facial mask comprises hirudin antiaging lyophilized facial mask and hirudin whitening lyophilized facial mask;
the hirudin anti-aging freeze-dried mask consists of active ingredients and auxiliary materials, wherein the active ingredients comprise: 0.2-8 parts of hirudin extract; the auxiliary materials comprise the following components: 1 to 99 parts of water, 1 to 50 parts of hydroxyethyl urea, 1 to 30 parts of sodium hyaluronate, 0.1 to 20 parts of jojoba seed oil, 0.25 to 10 parts of glycerin, 0.25 to 10 parts of trehalose, 0.2 to 10 parts of betaine, 0.1 to 8 parts of hydroxyethyl cellulose, 0.05 to 7 parts of fructo-oligosaccharide, 0.05 to 7 parts of collagen, 0.05 to 5 parts of squalane, 0.01 to 5 parts of polyglycerol-2 oleate and 0.01 to 2 parts of tremella fruit body extract;
the hirudin whitening freeze-dried mask consists of active ingredients and auxiliary materials, wherein the active ingredients comprise: hirudin extract, collagen, oligopeptide-10, oligopeptide-3, and allantoin; the auxiliary materials comprise the following components: mannitol, trehalose, sodium hyaluronate with molecular weight of 8000 dalton, sodium hyaluronate with molecular weight of 130 kilodalton, disodium hydrogen phosphate, sodium dihydrogen phosphate, glycerol and solvent;
preferably, the hirudin extract comprises 3 parts of water 50 parts, 20 parts of hydroxyethyl urea, 10 parts of sodium hyaluronate, 5 parts of jojoba seed oil, 3 parts of glycerin, 3 parts of trehalose, 3 parts of betaine, 1 part of hydroxyethyl cellulose, 0.8 part of collagen, 0.7 part of squalane, 0.3 part of polyglycerol-2 oleate and 0.2 part of tremella fruit body extract;
preferably, 1.2 parts of hirudin extract, 70 parts of water, 9 parts of hydroxyethyl urea, 6 parts of sodium hyaluronate, 5 parts of jojoba seed oil, 2 parts of glycerin, 2 parts of trehalose, 1.2 parts of betaine, 1.2 parts of fructo-oligosaccharide, 0.7 part of hydroxyethyl cellulose, 0.6 part of fructo-oligosaccharide, 0.54 part of collagen, 0.52 part of squalane, 0.03 part of polyglycerol-2 oleate and 0.01 part of tremella fruit body extract;
preferably, the hirudin extract comprises 1% of hirudin extract, 1.5% of collagen, 10.5% of oligopeptide, 30.5% of oligopeptide and 0.5% of allantoin; 2.5% of mannitol, 2.5% of trehalose, 0.25% of sodium hyaluronate with molecular weight of 8000 daltons, 0.25% of sodium hyaluronate with molecular weight of 130 kilodaltons, 0.15% of disodium hydrogen phosphate, 0.12% of sodium dihydrogen phosphate, 2% of glycerol and a solvent;
preferably, the hirudin extract comprises 1.5%, collagen 1.8%, oligopeptide-10.6%, oligopeptide-30.8% and allantoin 0.6%; 3% of mannitol, 2.5% of trehalose, 0.28% of sodium hyaluronate with molecular weight of 8000 daltons, 0.28% of sodium hyaluronate with molecular weight of 130 kilodaltons, 0.25% of disodium hydrogen phosphate, 0.14% of sodium dihydrogen phosphate, 3% of glycerol and a solvent;
preferably, the hirudin extract is 2%, collagen is 2%, oligopeptide-11%, oligopeptide-31.5%, and allantoin is 0.8%; 3% of mannitol, 3.5% of trehalose, 0.35% of sodium hyaluronate with molecular weight of 8000 daltons, 0.29% of sodium hyaluronate with molecular weight of 130 kilodaltons, 0.25% of disodium hydrogen phosphate, 0.15% of sodium dihydrogen phosphate and 4% of glycerin;
preferably, the solvent is deionized water or purified water.
The invention also aims to provide a preparation method of the hirudin freeze-dried mask, which comprises the following steps:
s1: dissolving the effective components in distilled water, and filtering with a 0.22 μm pore size filter membrane to obtain solution 1;
s2: dissolving auxiliary materials in deionized water to obtain a solution 2;
s3: mixing the solution 1 and the solution 2 to obtain a facial mask essence;
s4: sterilizing the mask cloth, folding, and immersing in mask essence; standing for 30-35 min until the mask cloth fully absorbs the mask essence;
s5: pushing the processed semi-finished product swing disc into a freeze dryer, rapidly cooling to-20 to-80 ℃, and keeping for 2-6 hours;
s6: after the base cloth and the material body are completely crystallized, vacuumizing is started to carry out sublimation drying; the sublimation drying time is 20-28 hours, and the air is discharged out of the box after the drying is finished;
s7: and rapidly filling the freeze-dried product into a mask packaging bag, carrying out cobalt radiation sterilization treatment in the mask packaging bag, vacuumizing the mask packaging bag in a nitrogen environment, and sealing to obtain the hirudin freeze-dried mask product.
The beneficial effects of the invention are as follows:
compared with the prior art, the hirudin freeze-dried mask provided by the invention overcomes the defect that functional components such as peptides are easy to inactivate in a liquid environment; the preservative must be added in the liquid form, so that the skin is irritated and allergic; and product ingredients in liquid form and instability problems; the active raw materials of the product are stable and effective, so that unnecessary addition of preservatives and the like is avoided, and the product is more friendly to the skin; experiments prove that the cream has definite anti-aging and whitening effects.
Drawings
FIG. 1 is a graph showing the comparison of anticoagulation activity;
FIG. 2 is a graph of the results of fishy smell sensory scores;
FIG. 3 is a graph showing the comparison of the free radical elimination rates of hirudin and VC DPPH;
FIG. 4 is a graph showing the comparison of the rate of radical elimination of hydroxyl groups between hirudin and VC;
FIG. 5 is the effect of hirudin and arbutin on B16 intracellular tyrosinase activity;
FIG. 6 is the effect of hirudin and arbutin on melanin synthesis in B16 cells;
FIG. 7 is a diagram showing the result of the construction of the chloasma model;
FIG. 8 is a graph of the results of HE dye verification modeling success for the normal and model sets;
fig. 9 is a graph showing the result of the change of back skin lesions by adding ultraviolet irradiation to progesterone administration for 30 days;
FIG. 10 is a graph showing the results of gray scale ratio after administration;
FIG. 11 is a graph showing MDA content versus results.
Detailed Description
The following description of the technical solutions in the embodiments of the present invention will be clear and complete, and it is obvious that the described embodiments are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Example 1
In this example, raw materials were weighed out sequentially, 6.437 kg of water, 0.8 kg of hydroxyethyl urea, 0.7 kg of sodium hyaluronate, 0.6 kg of jojoba seed oil, 0.5 kg of glycerin, 0.3 kg of trehalose, 0.2 kg of betaine, 0.2 kg of hirudin, 0.1 kg of hydroxyethyl cellulose, 0.05 kg of fructo-oligosaccharide, 0.05 kg of collagen, 0.032 kg of squalane, 0.021 kg of polyglycerol-2 oleate, and 0.01 kg of tremella fruit body extract group. The freeze-dried mask product is prepared according to the following steps:
the raw materials weighed above are prepared into a freeze-dried mask according to the following steps:
s1: preparing water solution of 4 kg of water, hydroxyethyl urea, sodium hyaluronate, jojoba seed oil, glycerol, trehalose, betaine, hydroxyethyl cellulose, fructo-oligosaccharide, collagen, squalane, polyglycerol-2 oleate, tremella fruit body extract group and other raw materials according to a proportion to obtain solution 1;
s2: dissolving hirudin in the residual water, and filtering with a filter membrane with pore diameter of 0.22 μm to obtain solution 2;
s3: uniformly mixing the solution 1 and the solution 2 to obtain a facial mask essence;
s4: sterilizing the mask cloth, and well folding and soaking the mask cloth in mask essence according to a fixed folding method;
s5: standing for 30 minutes until the mask base cloth fully absorbs the full material;
s6: pushing the processed semi-finished product swing disc into a freeze dryer, rapidly cooling to-20 ℃, and keeping for 2 hours;
s7: after the base cloth and the material body in the bottle are completely crystallized, vacuum pumping is started to carry out sublimation drying at 23 pa;
s8: the sublimation drying time is 21 hours, and the air is discharged out of the box after the drying is finished;
s9: and rapidly filling the freeze-dried product into a mask packaging bag, sterilizing the mask packaging bag, vacuumizing the mask packaging bag in a nitrogen environment, and sealing to obtain the hirudin freeze-dried mask product.
Example 2
In this example, raw materials were weighed out in order, 6 kg of water, 1 kg of hydroxyethyl urea, 0.8 kg of sodium hyaluronate, 0.5 kg of jojoba seed oil, 0.4 kg of glycerin, 0.3 kg of trehalose, 0.3 kg of betaine, 0.25 kg of hirudin, 0.2 kg of hydroxyethyl cellulose, 0.1 kg of fructo-oligosaccharide, 0.1 kg of collagen, 0.03 kg of squalane, 0.01 kg of polyglycerol-2 oleate, and 0.01 kg of tremella fruit body extract group. The freeze-dried mask product is prepared according to the following steps:
the freeze-dried mask was prepared according to the method of example 1, except that the freeze dryer was rapidly cooled to-30 ℃ for 2.5 hours; vacuum was applied to the mixture at 30pa and sublimation drying was performed for 25 hours.
Example 3
In this example, raw materials were weighed out in order, 7 kg of water, 0.6 kg of hydroxyethyl urea, 0.5 kg of sodium hyaluronate, 0.45 kg of jojoba seed oil, 0.35 kg of glycerin, 0.32 kg of trehalose, 0.27 kg of betaine, 0.18 kg of hirudin, 0.1 kg of hydroxyethyl cellulose, 0.08 kg of fructo-oligosaccharide, 0.07 kg of collagen, 0.05 kg of squalane, 0.015 kg of polyglycerol-2 oleate, and 0.015 kg of tremella fruit body extract group. The freeze-dried mask product is prepared according to the following steps:
the freeze-dried mask was prepared according to the method of example 1, except that the freeze dryer was rapidly cooled to-40 ℃ for 1.9 hours; sublimation drying was performed for 18 hours by vacuum 45 pa.
Example 4
In this example, raw materials were weighed out sequentially, 7.017 kg of water, 0.68 kg of hydroxyethyl urea, 0.55 kg of sodium hyaluronate, 0.47 kg of jojoba seed oil, 0.32 kg of glycerin, 0.27 kg of trehalose, 0.22 kg of betaine, 0.19 kg of hirudin, 0.08 kg of hydroxyethyl cellulose, 0.07 kg of fructo-oligosaccharide, 0.06 kg of collagen, 0.05 kg of squalane, 0.012 kg of polyglycerol-2 oleate, and 0.011 kg of tremella fruit body extract group. The freeze-dried mask product is prepared according to the following steps:
the freeze-dried mask was prepared according to the method of example 1, except that the freeze dryer was rapidly cooled to-45 ℃ for 2.3 hours; sublimation drying was performed for 23 hours by evacuating 48 pa.
Example 5
In this example, raw materials were weighed out sequentially, 8.011 kg of water, 0.5 kg of hydroxyethyl urea, 0.32 kg of sodium hyaluronate, 0.28 kg of jojoba seed oil, 0.21 kg of glycerin, 0.2 kg of trehalose, 0.145 kg of betaine, 0.14 kg of hirudin, 0.06 kg of hydroxyethyl cellulose, 0.05 kg of fructo-oligosaccharide, 0.041 kg of collagen, 0.032 kg of squalane, 0.006 kg of polyglycerol-2 oleate, and 0.005 kg of tremella fruit body extract group. The freeze-dried mask product is prepared according to the following steps:
the freeze-dried mask was prepared according to the method of example 1, except that the freeze dryer was rapidly cooled to-48 ℃ for 1.8 hours; vacuum was applied at 50pa and sublimation drying was performed for 30 hours.
Example 6
In this embodiment, the raw materials of efficacy, collagen, oligopeptide-1, oligopeptide-3 and hirudin are prepared in sequence, and the auxiliary materials comprise the following components according to the final concentration: mannitol, trehalose, sodium hyaluronate with molecular weight of 8000 dalton, sodium hyaluronate with molecular weight of 130 kilodalton, disodium hydrogen phosphate, sodium dihydrogen phosphate and glycerol, and the solvent is deionized water.
The freeze-dried mask product is prepared according to the following steps:
the raw materials prepared above are prepared into a freeze-dried mask according to the following steps:
s1: dissolving collagen, oligopeptide-1, oligopeptide-3 and hirudin in water according to a certain proportion to obtain a solution A;
s2: filtering the solution A by using a filter membrane with the pore diameter of 0.22 micron to obtain a solution 1;
s3: mixing part of deionized water with mannitol, trehalose, sodium hyaluronate with molecular weight of 8000 daltons, sodium hyaluronate with molecular weight of 130 kilodaltons, disodium hydrogen phosphate and sodium dihydrogen phosphate to obtain facial mask essence;
s4: sterilizing the mask cloth, and well folding and soaking the mask cloth in mask essence according to a fixed folding method;
s5: standing for 30 minutes until the mask base cloth fully absorbs the full material;
s6: pushing the processed semi-finished product swing disc into a freeze dryer, rapidly cooling to-20 ℃, and keeping for 2 hours;
s7: after the base cloth and the material body in the bottle are completely crystallized, vacuum pumping is started to carry out sublimation drying at 23 pa;
s8: the sublimation drying time is 21 hours, and the air is discharged out of the box after the drying is finished;
s9: and rapidly filling the freeze-dried product into a mask packaging bag, sterilizing the mask packaging bag, vacuumizing the mask packaging bag in a nitrogen environment, and sealing to obtain the hirudin freeze-dried mask product.
Example 7
In this example, raw materials for efficacy, collagen 1.5%, oligopeptide-10.5%, oligopeptide-30.6% and hirudin 1.5% were prepared in sequence, and the auxiliary materials comprise, according to the composition of the final concentration: mannitol 2.5%, trehalose 2.5%, sodium hyaluronate 0.25% with molecular weight 8000 daltons, sodium hyaluronate 15% with molecular weight 130 ten thousand daltons, disodium hydrogen phosphate 0.14%, sodium dihydrogen phosphate 0.12%, glycerin 2%, and partially deionized water.
The freeze-dried mask product is prepared according to the following steps:
the freeze-dried mask was prepared according to the method of example 1, except that the freeze dryer was rapidly cooled to-30 ℃ and held for 3 hours; vacuum was applied to the mixture at 30pa and sublimation drying was performed for 25 hours.
Example 8
In this example, raw materials for efficacy, collagen 2.5%, oligopeptide-11.5%, oligopeptide-30.8% and hirudin 1.8% were prepared in sequence, and the auxiliary materials comprise, according to the composition of the final concentration: mannitol 2.8%, trehalose 2.5%, sodium hyaluronate 0.45% with molecular weight 8000 daltons, sodium hyaluronate 0.15% with molecular weight 130 ten thousand daltons, disodium hydrogen phosphate 0.18%, sodium dihydrogen phosphate 0.15%, glycerol 3%, and partially deionized water.
The freeze-dried mask product is prepared according to the following steps:
the freeze-dried mask was prepared according to the method of example 1, except that the freeze dryer was rapidly cooled to-40 ℃ for 2 hours; vacuum 45pa was applied to sublimation dry for 20 hours.
The freeze-dried mask was prepared according to the method of example 1, except that the freeze dryer was rapidly cooled to-48 ℃ for 1.8 hours; vacuum was applied at 50pa and sublimation drying was performed for 30 hours.
Example 9
Comparative example 1
The difference from the mask prepared in example 1 and example 6 described above is that comparative example 1 was not subjected to lyophilization treatment, and the remaining component contents and preparation methods were the same as in example 1 and example 6. Hirudin is unstable in water, has bad taste after 7 days and has reduced activity.
Comparative example 2
The mask prepared in example 1 and example 6 was different from the mask prepared in example 1 and example 6 in that the hirudin solution was not filtered, and the content of the remaining components and the preparation method of comparative example 2 were as described in example 1 and example 6. The bacterial content of the product cannot be guaranteed to be in compliance by filtration and sterilization.
Comparative example 3
The mask produced in example 1 and example 6 was different from the mask produced in example 1 and example 6 in that the solution 1 was sterilized at high temperature, and the content of the remaining components and the preparation method were as described in example 1 and example 6. The hirudin is deactivated after high temperature sterilization.
Example 10
Hirudin deodorization process
Extracting hirudin at a feed liquid ratio of 20:1g/ml, performing ultrasonic treatment for 30min for three times, mixing the extractive solutions, performing deodorization treatment on the combined supernatant, performing freeze-drying, and then performing measurement on the hirudin. Titration was performed with 40NIH/mL thrombin solution and 20NIH/mL thrombin solution was used near the endpoint. The thrombin volume was 1-5. Mu.L and titrated with a titration volume of 1. Mu.L near the endpoint. The volume of the thrombin solution is 5 mu L each time, the thrombin is stirred by a syringe needle once each time, and the thrombin solution is titrated every 1min and is finished within 10min when the time is close to the time limit. Calculating activity; sample solution activity = Σthrombinconcentration x drop volume, thereby converting the sample hirudin content. As shown in fig. 1, 1 is the original, 2 is the anticoagulation activity after water extraction treatment, 3 to 8 are the anticoagulation activities after different deodorizing methods, and 3 has the best anticoagulation effect compared with 2, and 2 and 3 have significant differences compared with 1 (P < 0.05).
Finally, the test was sensory rated by a panel of 10 panelists (22-26 years old, 5 men and women each). The fishy smell evaluation of the experiment adopts 10 minutes, the distilled water without fishy smell is 0 minutes, the untreated hirudin is 10 minutes, the sample is put into a tube during evaluation, and an evaluator performs sensory evaluation according to the evaluation rule and finally takes the average value as the final score. The score is 0-2, and no fishy smell is basically generated; 2-4, little fishy smell; 4 to 6, fishy smell; 6-8: the fishy smell is obvious; 8-10, strong fishy smell. And screening the optimal fishy smell removing process by taking antithrombin activity and sensory evaluation as indexes. The hirudin antithrombin activity treated by the method is 511.1ATU/g, and the sensory evaluation score is 3 minutes. The conclusion is that the purification method 3 has the best fishy smell removing effect on the hirudin, and simultaneously the antithrombin activity is preserved to the greatest extent. As shown in FIG. 2, the original form is water extraction treatment, the deodorizing effect of 2-8 different deodorizing effects is the best compared with the original form, and the method for purifying the deodorizing effect of 2 is determined by combining the anticoagulation effect of 2.
Example 11
Determination of antioxidant Activity in vitro
Determination of DPPH radical scavenging ability
Mask samples with mass concentrations of 5, 2.5, 1.25, 0.625 and 0.3125mg/mL were prepared with distilled water. Taking 0.7mL of samples with different mass concentrations, adding 1.3mL of 0.3mmol/L DPPH ethanol solution, and measuring the absorbance value of the mixture at the wavelength of 517nm after the light-shielding reaction is completed, wherein VC is used as a reference; as shown in fig. 3;
wherein: a0 is a blank control absorbance value, A1 is a sample solution absorbance value, and A2 is an absolute ethyl alcohol and sample solution absorbance value;
determination of the ability to scavenge hydroxyl radicals
Mask samples with mass concentrations of 5, 2.5, 1.25, 0.625 and 0.3125mg/mL were prepared with distilled water. Adding 0.2mL of a ferrous sulfate solution and a salicylic acid-ethanol solution with the concentration of 6mmol/L into a reaction system in sequence, adding 0.2mL of a hydrogen peroxide solution with the concentration of 0.2mL of each sample solution with the concentration of 0.2mL of 6mmol/L, reacting for 1h at 37 ℃, and measuring the absorbance value of the mixture at the wavelength of 510nm after the reaction is completed. As shown in fig. 4;
wherein: a0 is a blank control absorbance value, A1 is a sample absorbance value, and A2 is a sample background absorption without salicylic acid-ethanol solution.
Example 12
1) Determination of tyrosinase activity in B16 cells
Culturing in 96-well plate, adding B16 single cell suspension (7-8). Times.10 3 After 24h of adherence, adding culture medium containing samples with different mass concentrations, wherein 3 compound holes are arranged in each mass concentration. The control group replaced the sample solution with RPMI-1640 complete medium. 37 ℃,5% CO 2 After incubation for 72h under conditions, the supernatant was discarded. Washing with PBS (pH=7.4) for 2 times, adding 50 μl of 1% octyl phenol polyoxyethylene ether (Triton X-100) solution into each well, rapidly freezing at-80deg.C for 30min, thawing at room temperature to completely rupture cells, pre-warming at 37deg.C for 5min, adding 10 μl of 1% L-DOPA solution, reacting at 37deg.C for 2 hr, and adding enzymeThe absorbance was measured at 490 nm. Tyrosinase activity inhibition was calculated as inhibition=1- (average absorbance of sample group/average absorbance of control group) ×100%.
2) Determination of melanin content in B16 cells
B16 cells in logarithmic growth phase were grown at a density of 5×10 4 Each of the cells was inoculated into a 6-well plate at a volume of 2mL per well, and cultured for 24 hours in a conventional manner. The culture solutions of samples with different mass concentrations are replaced, the control group is added with fresh complete culture medium with the same volume, and 3 parallel compound holes are arranged in each group. At 37℃with 5% CO 2 After culturing at saturated humidity for 72 hours, the supernatant was discarded. Each well is washed once by PBS, 0.5mL of trypsin digestion liquid with the mass concentration of 5g/L is added into the culture box at 37 ℃ for digestion for 2 to 4 minutes, and the whole digestion of cells is ensured by observation under a microscope. Digestion was stopped by adding 1mL of RPMI-1640 complete medium, gently beating the cells and collecting them into a 1.5mL centrifuge tube, centrifuging at 10000r/min for 10min, discarding the supernatant, adding 1mL of 1mol/LNaOH aqueous solution containing 10% (volume fraction) DMSO, sealing the centrifuge tube with a sealing film, heating in 80℃water bath for 30min, and measuring absorbance at 405 nm. The inhibition ratio of the sample to melanin synthesis was calculated according to formula (4). Melanin synthesis inhibition = (1-sample group average absorbance/control group average absorbance) ×100%.
Example 13
Evaluation of anti-aging Activity in vivo
Grouping, modeling and administration of experimental animals
1) 30 guinea pigs were randomly divided into a normal group (6) and an experimental group (24), and skin shaves Mao Beiyong were performed on the back of about 3cm×3 cm. The normal group is not specially treated; the experimental group is to inject progesterone into the root of the back leg of a guinea pig, 7.5mg/kg/d,1 d/time, alternate left and right legs, continuously inject the mould for 30d, and simultaneously irradiate the back exposed skin (the ultraviolet lamp is about 20cm from the back of the guinea pig) with medium wave ultraviolet rays (ultraviolet lamp of Shanghai Ji Guang special illumination electric appliances Co., ltd.) with the wavelength of 280-320 nm every day, 1 time/d, 60 min/time and 30d.
2) 6 guinea pigs in the experimental group and the normal group are randomly selected, heart blood is extracted for SOD and MDA detection, and the whole skin tissue at the skin lesion position of about 1.0cm multiplied by 1.0cm at the back is taken for HE and immunohistochemical staining. The experimental groups were divided into A, B, C groups at random, with 6 groups each, with the remaining 18 model groups. After the group A is treated and skin reaction is closely observed, the group B is smeared with vitamin E ointment at the back focus skin lesion of the chloasma mice for 1 time/d; group C did not make any special treatment. The test was performed after 1 month.
3) 6 guinea pigs of the experimental group and the normal group are randomly selected after the molding is successful, the heart blood is extracted for SOD and MDA detection, and the whole skin tissue at the skin lesion position of about 1.0cm multiplied by 1.0cm at the back is taken for HE and immunohistochemical staining. The experimental groups were divided into A, B, C groups at random, with 6 groups each, with the remaining 18 model groups. The group A is treated by a non-experimental group, and after skin reaction is closely observed, the group B is smeared with vitamin E ointment at the lesion skin of the back part of the chloasma mouse for 1 time/d; group C was blank without any special treatment. The local smearing medicine is calculated according to the proportion for 1 time/d and the medicine is continuously used for 30 days. The blank groups were applied with distilled water locally for 1 time/d for the same time as the experimental groups. All guinea pigs were sacrificed 1 day after the last dose, and each guinea pig was promptly harvested at the dehairing site for 2 pieces of skin tissue for later use. MDA content detection is carried out after the tissue is treated, and is shown in Table 1, and SOD activity is measured.
TABLE 1MDA content detection
Experiments show that the Hirudo manillensis extract has the effects of eliminating DPPH free radical, and has strong capability of eliminating hydroxyl free radical, and can effectively inhibit tyrosinase activity and inhibit melanin synthesis, so that the hirudin extract has an antioxidation effect; can lighten chloasma, and has the effects of whitening and lightening chloasma.
Example 14
Stability test
The products are placed in a constant temperature and humidity box (the temperature is 40 ℃ and the relative humidity is 75%) for 6 months, and sampling and detection are carried out respectively at 0 month, 1 month, 2 month, 3 month and 6 month. Long-term test the products were placed in a constant temperature and humidity cabinet (temperature 25 ℃, relative humidity 60%) and sampled and measured at 0, 3, 6, 12 months.
Table 2 stability of hirudin extract of examples and comparative examples
/>
Example 15
Human safety evaluation test
The repeated open type smearing test uses forearm flexor side as tested part, and the area is 3×3cm 2 The tested part should be kept dry to avoid contacting with other external preparations. The test object is uniformly applied to the test site about 0.050, 0.005g (mL)/time, 2 times daily for 7 consecutive days while observing skin reaction, and whether to continue the test should be determined according to circumstances during the course of such skin reaction as occurrence of 3 minutes or more. Skin reactions were observed according to the skin reaction evaluation criteria of the repeated open-type smear test of table 3, and the results were recorded.
TABLE 3 skin reaction evaluation criteria for open-type skin repeatability application test
TABLE 4 skin response score for skin repetitive open spread test
Group of | Example 1 | Example 2 | Example 3 | Example 4 | Example 5 | Example 6 |
Scoring of | 0.03 | 0.02 | 0.03 | 0.01 | 0.01 | 0.04 |
Group of | Example 7 | Example 8 | Comparative example 1 | Comparative example 2 | Comparative example 3 | |
Scoring of | 0.03 | 0.03 | 1.56 | 1.18 | 0.02 |
TABLE 5 mask evaluation criteria
Sensory index | Description of the invention |
Texture of texture | 1-10 min, the higher the fraction, the thicker the texture of the material |
Smell of | 1-10 min, the higher the score, the more comfortable the smell sense |
Irritation (irritation) | 1-10 min, the higher the fraction, the less irritating |
Sense of heaviness | 1 to 10 minutes, the higher the fraction, the lighter the sensation of the body, and the no burden on the skin |
Table 6 mask scoring
Group of | Example 1 | Example 2 | Example 3 | Example 4 | Example 5 | Example 6 |
Scoring of | 7.54 | 7.69 | 8.01 | 7.95 | 8.56 | 7.58 |
Group of | Example 7 | Example 8 | Comparative example 1 | Comparative example 2 | Comparative example 3 | |
Scoring of | 7.85 | 8.05 | 3.28 | 5.56 | 7.05 |
According to the feedback, the hirudin freeze-dried mask prepared by the invention can avoid the over-quick inactivation of the hirudin in a liquid environment by the freeze-dried mask technology, so that the storage time of the mask can be prolonged, and the activity of the mask can be maintained. The results show that the hirudin freeze-dried mask prepared by the invention has good skin feel, good efficacy and little skin irritation, and gives comfortable and safe care to fragile skin.
Claims (8)
1. The hirudin freeze-dried mask is characterized by comprising a hirudin anti-aging freeze-dried mask and a hirudin whitening freeze-dried mask;
the hirudin anti-aging freeze-dried mask consists of active ingredients and auxiliary materials, wherein the active ingredients comprise: 0.2-8 parts of hirudin extract; the auxiliary materials comprise the following components: 1 to 99 parts of water, 1 to 50 parts of hydroxyethyl urea, 1 to 30 parts of sodium hyaluronate, 0.1 to 20 parts of jojoba seed oil, 0.25 to 10 parts of glycerin, 0.25 to 10 parts of trehalose, 0.2 to 10 parts of betaine, 0.1 to 8 parts of hydroxyethyl cellulose, 0.05 to 7 parts of fructo-oligosaccharide, 0.05 to 7 parts of collagen, 0.05 to 5 parts of squalane, 0.01 to 5 parts of polyglycerol-2 oleate and 0.01 to 2 parts of tremella fruit body extract;
the hirudin whitening freeze-dried mask consists of active ingredients and auxiliary materials, wherein the active ingredients comprise: hirudin extract, collagen, oligopeptide-10, oligopeptide-3, and allantoin; the auxiliary materials comprise the following components: mannitol, trehalose, sodium hyaluronate with molecular weight of 8000 dalton, sodium hyaluronate with molecular weight of 130 kilodalton, disodium hydrogen phosphate, sodium dihydrogen phosphate, glycerol and solvent.
2. The hirudin lyophilized mask of claim 1, wherein the hirudin extract comprises 3 parts, 50 parts of water, 20 parts of hydroxyethyl urea, 10 parts of sodium hyaluronate, 5 parts of jojoba seed oil, 3 parts of glycerin, 3 parts of trehalose, 3 parts of betaine, 1 part of hydroxyethyl cellulose, 0.8 part of collagen, 0.7 part of squalane, 0.3 part of polyglycerol-2 oleate, and 0.2 part of tremella fruit body extract.
3. The hirudin lyophilized mask of claim 1, wherein the hirudin extract is 1.2 parts, water is 70 parts, hydroxyethylurea is 9 parts, sodium hyaluronate is 6 parts, jojoba seed oil is 5 parts, glycerin is 2 parts, trehalose is 2 parts, betaine is 1.2 parts, fructo-oligosaccharide is 1.2 parts, hydroxyethylcellulose is 0.7 parts, fructo-oligosaccharide is 0.6 parts, collagen is 0.54 parts, squalane is 0.52 parts, polyglycerol-2 oleate is 0.03 parts, tremella fruit body extract is 0.01 parts.
4. The hirudin lyophilized mask of claim 1, wherein the hirudin extract is 1%, collagen is 1.5%, oligopeptide-10.5%, oligopeptide-30.5%, allantoin is 0.5%; mannitol 2.5%, trehalose 2.5%, sodium hyaluronate 0.25% with molecular weight 8000 daltons, sodium hyaluronate 0.25% with molecular weight 130 ten thousand daltons, disodium hydrogen phosphate 0.15%, sodium dihydrogen phosphate 0.12%, glycerin 2%, and solvent.
5. The hirudin lyophilized mask of claim 1, wherein the hirudin extract is 1.5%, collagen is 1.8%, oligopeptide-10.6%, oligopeptide-30.8%, allantoin is 0.6%; mannitol 3%, trehalose 2.5%, sodium hyaluronate 0.28% with molecular weight 8000 daltons, sodium hyaluronate 0.28% with molecular weight 130 ten thousand daltons, disodium hydrogen phosphate 0.25%, sodium dihydrogen phosphate 0.14%, glycerol 3%, and solvent.
6. The hirudin lyophilized mask of claim 1, wherein the hirudin extract is 2%, collagen is 2%, oligopeptide-11%, oligopeptide-31.5%, allantoin is 0.8%; mannitol 3%, trehalose 3.5%, sodium hyaluronate 0.35% with molecular weight 8000 daltons, sodium hyaluronate 0.29% with molecular weight 130 ten thousand daltons, disodium hydrogen phosphate 0.25%, sodium dihydrogen phosphate 0.15%, glycerin 4%, and solvent.
7. The hirudin lyophilized mask of claim 1, wherein the solvent is deionized water or purified water.
8. The preparation method of the hirudin freeze-dried mask is characterized by comprising the following steps of:
s1: dissolving the effective components in distilled water, and filtering with a 0.22 μm pore size filter membrane to obtain solution 1;
s2: dissolving auxiliary materials in deionized water to obtain a solution 2;
s3: mixing the solution 1 and the solution 2 to obtain a facial mask essence;
s4: sterilizing the mask cloth, folding, and immersing in mask essence; standing for 30-35 min until the mask cloth fully absorbs the mask essence;
s5: pushing the processed semi-finished product swing disc into a freeze dryer, rapidly cooling to-20 to-80 ℃, and keeping for 2-6 hours;
s6: after the base cloth and the material body are completely crystallized, vacuumizing is started to carry out sublimation drying; the sublimation drying time is 20-28 hours, and the air is discharged out of the box after the drying is finished;
s7: and rapidly filling the freeze-dried product into a mask packaging bag, carrying out cobalt radiation sterilization treatment in the mask packaging bag, vacuumizing the mask packaging bag in a nitrogen environment, and sealing to obtain the hirudin freeze-dried mask product.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310003683.5A CN117297996A (en) | 2023-01-03 | 2023-01-03 | Hirudin freeze-dried mask and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310003683.5A CN117297996A (en) | 2023-01-03 | 2023-01-03 | Hirudin freeze-dried mask and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117297996A true CN117297996A (en) | 2023-12-29 |
Family
ID=89254154
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310003683.5A Pending CN117297996A (en) | 2023-01-03 | 2023-01-03 | Hirudin freeze-dried mask and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117297996A (en) |
-
2023
- 2023-01-03 CN CN202310003683.5A patent/CN117297996A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20100135871A (en) | Active ingredient that stimulates the proliferation and/or activity of fibroblasts | |
CN110664650A (en) | Multi-effect skin care composition and essence and preparation method thereof | |
CN110787100A (en) | Anti-allergy skin-soothing essence and preparation method thereof | |
JPH0840882A (en) | Sheet for plastering skin | |
CN111265441A (en) | Composition capable of enhancing skin night repair and regeneration capacity and application thereof | |
KR101046438B1 (en) | Cosmetic composition containing a mixed plant extract having a skin wrinkle improvement and skin astringent action and a method of manufacturing the same | |
CN111743826A (en) | Freckle-removing, wrinkle-resisting and moisturizing emulsion | |
CN111870541A (en) | Herbal whitening compound composition, mask and preparation method thereof | |
CN115414299B (en) | Freeze-dried spray for relieving and repairing | |
CN111568781A (en) | Skin care gel and preparation method thereof | |
KR101978698B1 (en) | Cosmetic composition for skin care comprising onion extracts | |
CN110613663A (en) | Skin repairing composition, skin care product and preparation method thereof | |
KR20160084825A (en) | composition for preventing and alleviating ultraviolet-induced skin damage and cosmetic comprising the same | |
CN117297996A (en) | Hirudin freeze-dried mask and preparation method thereof | |
CN114159341A (en) | Freeze-dried eye patch and preparation method thereof | |
KR102054100B1 (en) | Cosmetic composition containing fermented extract of roots | |
CN111067839A (en) | Conditioning repairing agent and preparation method thereof | |
CN108113916B (en) | Natural repair peptide mask liquid and preparation method thereof | |
KR101150373B1 (en) | Hair Growth Promoter Using Low Temperature Nano Extraction Method Having Copper-peptide And Manufacturing Method Thereof | |
KR100861415B1 (en) | Method of preparing cosmetics composition and cosmetics for anti-oxidation and skin-calming, prepared therefrom | |
KR101150374B1 (en) | Hair Growth Promoter Using Low Temperature Nano Extraction Method Having Soy-Oligo-Peptide And Manufacturing Method Thereof | |
CN110201024A (en) | A kind of composition of the extract containing stem cell of wound healing and application thereof | |
CN116942569B (en) | Essential oil composition containing kuquai oil and application thereof | |
KR101620950B1 (en) | Manufacturing method of the Cosmetic Composition for Regenerating Skin Cell, Anti-oxidant, Anti-bacterial effect and Anti-inflammatory of the skin and the Cosmetic Composition manufactured by the same | |
KR102238966B1 (en) | composition for preventing and alleviating ultraviolet-induced skin damage and cosmetic comprising the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240418 Address after: No. 118, Building 9, Shilin Street, University City, Chenggong District, Kunming City, Yunnan Province, 650504 Applicant after: Yunnan Kaibei Technology Co.,Ltd. Country or region after: China Address before: 650500 Yuehua street, Chenggong District, Kunming, Yunnan Province, No. 2929 Applicant before: YUNNAN MINZU University Country or region before: China |